Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2009

Sigma-Aldrich to Distribute Stemgent’s Gene Delivery Products for iPS Cells

  • Sigma-Aldrich entered into an exclusive, worldwide distribution agreement to offer Stemgent's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells. The reprogramming technologies offered under the terms of the agreement involve viral vectors from Stemgent, lentivirus technology from Sigma-Aldrich, and dox Inducible expression from TET Systems.

    “Induced pluripotent stem cells have emerged as immensely useful tools for the modeling of human diseases, research and development of therapeutics, regenerative medicine, and the development of personalized cell-replacement therapies,” comments David Smoller, Ph.D., president of Sigma-Aldrich's research biotech business unit.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »